Categories
Blood Cancer

CAR-T in multiple myeloma: cilta-cel & ide-cel [Video]

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, shares his thoughts on how the addition of ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) to the treatment paradigm is adding value to the treatment of patients with multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

CAR-T, bispecifics and MRD: how is treatment for multiple myeloma evolving? [Video]

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, gives his thoughts on how the treatment of multiple myeloma could evolve – including the continued use of CAR-Ts, the use of bispecific antibodies for maintenance therapy, and the importance of measurable residual disease (MRD) for patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

Future perspectives on CAR-T therapy for multiple myeloma [Video]

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, highlights some of the ongoing research in CAR-T therapy for multiple myeloma including increasing capacity and speed of production, as well as increasing expression of BCMA, and a new target being currently evaluated – GPRC5D. Prof. Munshi also notes that some patients treated with CAR-T are benefiting from longer-term maintenance, potentially paving the way for a cure in multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Breast Cancer

ADCs for the treatment of HER2-low breast cancer [Video]

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, reflects on the use of antibody-drug conjugates (ADCs) for the treatment of HER2-low breast cancer, including trastuzumab duocarmazine which was evaluated in the TULIP trial (NCT03262935), where it demonstrated activity in HER2-low patients, as well as disitamab vedotin which has shown similar response rates. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Blood Cancer

Collaboration in the myeloma community [Video]

In this video, Kenneth Anderson, MD, Dana-Farber Cancer Institute, Boston, MA, briefly highlights the importance of meetings such as COMy 2022 in bringing the myeloma community together and allowing clinicians, researchers, and patients, to share the latest updates in the field. Dr Anderson also comments on the commitment in the community, the importance of working together, and the future impact of novel immunotherapies on the field. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

Categories
Blood Cancer

Updates from the DETERMINATION trial: RVD vs. autoSCT in patients with multiple myeloma [Video]

In this video, Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses findings from the DETERMINATION trial (NCT01208662) evaluating the use of lenalidomide, bortezomib, and dexamethasone versus high-dose treatment with autologous stem cell transplantation (autoSCT) in patients with multiple myeloma. Dr Richardson first highlights some results from this trial, including the progression-free survival (PFS) observed in patients and the importance of transplant in controlling event-free survival (EFS). Dr Richardson then discusses the toxicities observed and further highlights other therapies changing the myeloma treatment landscape, including quadruplet therapies, monoclonal antibodies, CAR-T therapy, and bispecific T-cell engagers (BiTEs). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Blood Cancer

Advances in CAR-T therapy for lymphoma [Video]

In this discussion chaired by David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, Caron Jacobson, MD, MMSc, Dana Farber Cancer Institute, Boston, MA, and Loretta Nastoupil, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, talk on moving CAR-T therapy earlier in the treatment algorithm of high-risk large B-cell lymphoma (LCBL), and share their thoughts on the follow-up data of studies evaluating CAR-T therapy in mantle cell lymphoma (MCL) and follicular lymphoma (FL). Based on the results of the TRANSFORM (NCT03575351) and ZUMA-7 (NCT03391466) studies, the experts debate which LBCL patients should be selected to receive CAR-T therapy or autologous transplantation in the second-line setting. Additionally, Dr Maloney, Dr Jacobson and Dr Nastoupil comment on encouraging data from the ZUMA-12 study (NCT03761056) which provides strong evidence for further testing CAR-T therapy in the frontline setting. Moving forward, the experts talk on the efficacy of brexucabtagene autoleucel (brexu-cel) in MCL, and also talk on the updated data from the ZUMA-5 study (NCT03105336) in patients with FL, discussing the possibility of administering this therapy in the outpatient setting and of approaching a cure. This interview took place at the 4th International Workshop on CAR-T (iwCAR-T) 2022 held in Tampa, FL.

Categories
Breast Cancer

ctDNA and late recurrence in high-risk, HR+, HER2- breast cancer [Video]

Marla Lipsyc-Sharf, MD, Dana-Farber Cancer Institute, Boston, MA, discusses results of a study evaluating circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer. Of the 83 evaluable patients, 10% had detectable ctDNA more than 5 years after initial diagnosis. In addition, 6 patients developed distant metastatic recurrence, all 6 of which also tested positive for ctDNA prior to distant metastatic recurrence with a median lead time of 12.4 months. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Categories
Blood Cancer

The future of myeloma treatment and the possibility of cure [Video]

In this video, Kenneth Anderson, MD, Dana-Farber Cancer Institute, Boston, MA, gives an overview of the future treatment of myeloma and his presentation at COMy 2022. Dr Anderson highlights his presentation which covered a variety of topics, including novel technologies used to monitor myeloma, the application of therapeutic agents, advances in immunotherapy, and novel targets. Dr Anderson then goes on to discuss precision medicine and the role of novel immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapy, antibodies, bispecific T-cell engagers (BiTEs), and the importance of achieving measurable residual disease (MRD) negativity. To conclude, Dr Anderson addresses the possibility of achieving cure in myeloma by 2030. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

Categories
Blood Cancer

RNA profiling of circulating tumor cells in myeloma patients [Video]

Elizabeth D. Lightbody, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the value of investigating circulating tumor cells (CTCs) in patients with multiple myeloma. CTCs are present at all stages of the myeloma disease continuum, and CTC levels increase with disease progression. Dr Lightbody discusses some research in which single-cell RNA sequencing was performed on a subset of patients and healthy donors to analyze CTC profiles, and the value of using CTCs as a biomarker of disease. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.

Categories
Blood Cancer

The PANGEA model: improving risk stratification in multiple myeloma [Video]

In this video, Annie Cowan, BA, Dana-Farber Cancer Institute, Boston, MA, discusses the PANGEA model which uses continuous variables to predict the risk of progression for patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma. Ms Cowan first explains how the PANGEA model has improved and compares it to the current gold standard, which is the 20/2/20 model and the 2014 IMWG MGUS criteria. Following this, Ms Cowan details the additional variables and statistical analyses used in the PANGEA model, and how these factors improve the ability of this model to predict a patient’s risk of progression. Ms Cowan then discusses recent research which focuses on how to examine risk of progression without the use of bone marrow biopsies, and the various algorithms used in the PANGEA model. To conclude, Ms Cowan highlights the ability of this model to be used on an individual basis, and the role it will have in improving risk progression for patients in the future. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.

Categories
Blood Cancer

Defining precursor states in multiple myeloma [Video]

Annie Cowan, BA, Dana-Farber Cancer Institute, Boston, MA, discusses the two major classes of precursor multiple myeloma states: monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma. Ms Cowan then further explains these two precursor states, and how they are differentiated from one another based on levels of M proteins and percentage of bone marrow plasma cells. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.